Skip to main content
. Author manuscript; available in PMC: 2023 Mar 10.
Published in final edited form as: Cancer Res. 2020 Nov 25;81(3):698–712. doi: 10.1158/0008-5472.CAN-20-2066

Figure 3. Mertk deficiency decreases tumor malignancy and synergize with anti-PD1 immunotherapy in the E0771 murine breast cancer model.

Figure 3.

a. 5X104 E0771 WT cells were injected orthotopically in to the mammary fat pad of female c57BL/6- Mertk+/+ (WT) and Mertk−/− (Mertk KO) mice, and upon establishment of tumors, mice were treated with mIgG1 Isotype or anti-PD1 antibody (5 mg/kg) on day 6, 9, 12, and 15 and tumor growth determined by means tumor volume measurement every 3 days over the period of 5 weeks. (n=8/per group). Arrows indicate antibody injections. b. Kaplan-Meier curve showing percentage survival of tumor bearing mice upon anti-PD1 immunotherapy in the Mertk+/+ and Mertk−/− mice. c. Tumor free Mertk−/− mice treated with anti-PD1 immunotherapy were rechallenged with 1 X 105 or 2 X 105 E0771 WT cells d42 and d82 respectively, and tumor growth measurements were performed (n=16). d-e. Tumor growth curve (d.) and corresponding Kaplan-Meier curves (e.) showing percentage survival following injection of 5X104 E0771 WT or Axl KO tumor cells in to the mammary fat pad of female c57BL/6- Mertk+/+ and Mertk−/− mice.